Details for Patent: 8,067,427
✉ Email this page to a colleague
Which drugs does patent 8,067,427 protect, and when does it expire?
Patent 8,067,427 protects CAPRELSA and is included in one NDA.
This patent has forty patent family members in thirty-three countries.
Summary for Patent: 8,067,427
| Title: | Pharmaceutical compositions comprising ZD6474 |
| Abstract: | A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties. |
| Inventor(s): | Stott; Paul William (Wilmington, DE) |
| Assignee: | AstraZeneca AB (Sodertajle, SE) |
| Application Number: | 11/596,979 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,067,427
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,067,427
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0411378.3 | May 21, 2004 |
| PCT Information | |||
| PCT Filed | May 18, 2005 | PCT Application Number: | PCT/GB2005/001931 |
| PCT Publication Date: | December 01, 2005 | PCT Publication Number: | WO2005/112934 |
